Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cocrystal Pharma Inc COCP

Healthcare
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function... see more

Recent & Breaking News (NDAQ:COCP)

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

GlobeNewswire July 14, 2022

Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

GlobeNewswire June 1, 2022

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

GlobeNewswire May 11, 2022

Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

GlobeNewswire April 21, 2022

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

GlobeNewswire April 19, 2022

Cocrystal Pharma to Present at the Noble Capital Markets' NobleCon18 Conference

GlobeNewswire April 14, 2022

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

GlobeNewswire April 12, 2022

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

GlobeNewswire March 23, 2022

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

GlobeNewswire March 22, 2022

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

GlobeNewswire March 10, 2022

Cocrystal Pharma to Participate in Upcoming Investment Conferences

GlobeNewswire March 3, 2022

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

GlobeNewswire January 27, 2022

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

GlobeNewswire January 6, 2022

Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference

GlobeNewswire January 4, 2022

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

GlobeNewswire December 22, 2021

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

GlobeNewswire December 2, 2021

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

GlobeNewswire December 1, 2021

Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones

GlobeNewswire November 15, 2021

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

GlobeNewswire November 8, 2021